Expression of skin-derived antileukoproteinase (SKALP) in reconstructed human epidermis and its value as a marker for skin irritation.

For the investigation of the skin irritancy potential of chemicals in an in vitro model, it is necessary to have sensitive end-points that predict the effects on native human skin. Our aim was to investigate whether the induction of the proteinase inhibitor SKALP in reconstructed epidermis can be used as a marker. The influence of culture conditions and the effect of topical application of sodium lauryl sulfate and oleic acid on SKALP expression were evaluated using immunohistochemistry and Northern blotting. SKALP expression was induced by serum, epidermal growth factor and fibroblasts. In the presence of retinoic acid and 1,25-dihydroxyvitamin D3 SKALP expression was inhibited, whereas supplementation with ascorbic acid and a-tocopherol had no effect. Tape-stripping of excised skin and topical treatment with sodium lauryl sulfate induced SKALP protein expression. Application of sodium lauryl sulfate and oleic acid on reconstructed epidermis also induced SKALP at the protein level but no significant effects could be demonstrated at mRNA levels. In conclusion, SKALP expression, which was increased upon application of sodium lauryl sulfate and oleic acid, can be used as an in vitro end-point for skin irritancy, irrespective of the modifying effects of culture conditions.

[1]  J. Bouwstra,et al.  Culture of reconstructed epidermis in a defined medium at 33° C shows a delayed epidermal maturation, prolonged lifespan and improved stratum corneum , 1997, Archives of Dermatological Research.

[2]  L. Hudson,et al.  Enhanced Modulation of Keratinocyte Motility by Transforming Growth Factor-α (TGF-α) Relative to Epidermal Growth Factor (EGF) , 1996 .

[3]  P. Chomczyński,et al.  Substitution of chloroform by bromo-chloropropane in the single-step method of RNA isolation. , 1995, Analytical biochemistry.

[4]  J. Schalkwijk,et al.  Differential expression of SKALP/Elafin in human epidermal tumors. , 1993, The American journal of pathology.

[5]  L. Turka,et al.  Keratinocytes: key immunocytes of the integument. , 1993, The American journal of pathology.

[6]  J. Schalkwijk,et al.  Immunohistochemical localization of SKALP/elafin in psoriatic epidermis. , 1993, The Journal of investigative dermatology.

[7]  O. Wiedow,et al.  Elafin is a potent inhibitor of proteinase 3. , 1991, Biochemical and biophysical research communications.

[8]  J. Schalkwijk,et al.  Skin‐derived antileucoproteases (SKALPs): characterization of two new elastase inhibitors from psoriatic epidermis , 1990, The British journal of dermatology.

[9]  P. Kerkhof,et al.  Enzymatic quantification of polymorphonuclear leucocytes in normal and psoriatic skin following standardized injury , 1988, Clinical and experimental dermatology.

[10]  P. Kerkhof,et al.  Response of polymorphonuclear leukocytes to topical leukotriene B4 in healthy and psoriatic skin , 1987, British Journal of Dermatology.

[11]  J. Fraki,et al.  Degradation of the epidermal-dermal junction by proteolytic enzymes from human skin and human polymorphonuclear leukocytes , 1984, The Journal of experimental medicine.

[12]  J. Robotham,et al.  The acute-phase response. , 1995, New horizons.

[13]  M. Ponec,et al.  Use of human skin recombinants as an in vitro model for testing the irritation potential of cutaneous irritants. , 1995, Skin pharmacology : the official journal of the Skin Pharmacology Society.

[14]  L. Hudson,et al.  Regulation of gene expression by epidermal growth factor. , 1991, Genetic engineering.

[15]  M. Ponec.  Reconstruction of human epidermis on de-epidermized dermis: Expression of differentiation-specific protein markers and lipid composition. , 1991, Toxicology in vitro : an international journal published in association with BIBRA.